We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
- Authors
Milder, Tamara Y.; Lin, Jialing; Pearson, Sallie‐Anne; de Oliveira Costa, Juliana; Neuen, Brendon L.; Pollock, Carol; Jun, Min; Greenfield, Jerry R.; Day, Richard O.; Stocker, Sophie L.; Brieger, David; Falster, Michael O.
- Abstract
The article discusses the discontinuation of SGLT2 inhibitors (SGLT2i) in people with type 2 diabetes following hospitalization for heart failure. A study conducted in New South Wales, Australia, found that nearly 30% of SGLT2i users discontinued therapy within 90 days of discharge, with one in five remaining off treatment at 365 days. Factors such as age, hospitalization duration, number of prior hospitalizations, and chronic kidney disease were associated with higher discontinuation rates. The study highlights the importance of minimizing SGLT2i discontinuation to reduce mortality and readmission risks in this population.
- Subjects
SODIUM-glucose cotransporter 2 inhibitors; ANGIOTENSIN-receptor blockers; ACE inhibitors; DIAGNOSIS related groups; TYPE 2 diabetes diagnosis; DIABETIC acidosis; DRUGSTORES; PUBLIC hospitals
- Publication
Diabetes, Obesity & Metabolism, 2025, Vol 27, Issue 2, p997
- ISSN
1462-8902
- Publication type
Academic Journal
- DOI
10.1111/dom.16061